Purpose of Review

Anticoagulant use among patients is prevalent and increasing. It is important for anesthesiologists to be aware of patients on anticoagulants while performing regional anesthesia.

Recent Findings

In recent years, the FDA has approved many new anticoagulants. With new drugs coming to the market, new side effect profiles should be considered when treating patients, especially when using regional anesthesia. Both ASRA and European agencies have laid out recommendations regarding anticoagulant use and neuraxial/regional techniques. Regarding newer anticoagulants, the guidelines for discontinuation prior to neuraxial injection are based on pharmacokinetics, including half-life duration for each drug.

Summary

While each clinical scenario requires an individualized approach, general guidelines can serve as a starting point to help with anesthetic planning and potentially improve patient safety in this evolving field.

中文翻译：

---

抗凝疗法患者的区域麻醉-基于证据的建议。

审查目的

患者中抗凝剂的使用很普遍并且正在增加。对于麻醉医师而言，在进行区域麻醉时了解使用抗凝剂的患者非常重要。

最近的发现

近年来，FDA已经批准了许多新的抗凝剂。随着新药上市，在治疗患者时，尤其是在使用区域麻醉时，应考虑新的副作用。ASRA和欧洲机构都已就抗凝剂的使用和神经/区域技术提出了建议。对于较新的抗凝剂，神经注射前停药的指导原则是基于药代动力学的，包括每种药物的半衰期。

概要

尽管每种临床情况都需要个性化的方法，但一般指导原则可以作为帮助麻醉剂规划并在此不断发展的领域中潜在提高患者安全性的起点。